MFLRC Academy is live. On-demand regulatory training. Lesson 1 is free. Explore→

MFLRC Academy — on-demand training in Health Canada licensing, GMP and quality systems. Browse courses →

MFLRC - MF License & Regulatory Consultants

November 10, 2026 · Pharmaceuticals

Nitrosamine Guidance Update (November 2026): LTL Limits and What MAHs Must Do

By Mussarat Fatima

PharmaceuticalsRegulatory AffairsQuality Assurance
Nitrosamine Guidance Update (November 2026): LTL Limits and What MAHs Must Do

On 5 November 2026, Health Canada posted a revised version of its Guidance on Nitrosamine Impurities in Medications. Health Canada's guidance applies the less-than-lifetime (LTL) framework from ICH M7 to nitrosamine impurities, treating the Acceptable Intake (AI) limits as appropriate for both lifetime and less-than-lifetime use. This is an established part of the framework, not a new allowance, and the guidance limits how LTL-adjusted limits may be used: they are not to be applied during or after the three-year corrective-action window. The table of established AI limits has moved onto its own page, and the compliance window for corrective and preventive action is clearer. If your last nitrosamine risk assessment was written before the current guidance, parts of it may be out of date.

Executive summary

Nitrosamines are probable human carcinogens that can form in drug substances and drug products through several routes, including nitrosatable amines reacting with nitrite in excipients. Since 2019, Health Canada has required Market Authorization Holders (MAHs) to assess, test and, where needed, control these impurities. The core three-step program (risk assessment, confirmatory testing, changes to the market authorization) is complete on paper, because all three deadlines have passed. What remains is steady-state control: keeping risk assessments current, testing to validated methods, and reducing levels below the AI limits within the CAPA window.

Health Canada's guidance applies the ICH M7 less-than-lifetime approach to nitrosamines, with a scientifically justified, higher adjusted limit for products given for a defined short period rather than for a lifetime. It is not, however, a way to avoid reformulation: the guidance states that LTL-based AI limits are not to be applied during or after the three-year CAPA implementation timeline. Applying it still raises the stakes for getting treatment duration, maximum daily dose and the calculation right. This article explains how the LTL factors work, where the AI limits now live, and the practical steps a Canadian quality unit should take this quarter.

What changed in the November 2026 update

What it is: a revision to Health Canada's nitrosamine guidance, dated 5 November 2026, that mainly affects how AI limits can be adjusted and where the limits are published. Why it matters: it can change the pass or fail outcome of a risk assessment, especially for short-course medicines. What to do: re-read the current guidance, update your internal references to Appendix 1, and recalculate limits for any product where treatment duration is clearly less than a lifetime.

Three practical changes stand out:

  • Less-than-lifetime limits come with conditions. Health Canada's guidance applies the ICH M7 less-than-lifetime approach to nitrosamines and sets out the adjustment factors, but it also states that LTL-based AI limits are not to be applied during or after the three-year CAPA implementation timeline.
  • Appendix 1 has moved. The table of established AI limits has been removed from the guidance document and placed on a dedicated established Acceptable Intake limits page, maintained as a versioned list with an Excel download. Reference that page, not an old copy pasted into a procedure.
  • The CAPA window is explicit. For AI limits published before 1 August 2025, MAHs have up to three years from that date, meaning up to 1 August 2028, to implement corrective and preventive action. For AI limits published on or after 1 August 2025, the clock runs for up to three years from the publication date of that limit.

Nitrosamine impurities: a short definition

What they are: N-nitrosamines are compounds that contain a nitroso group bonded to a nitrogen atom. Several are classified as probable human carcinogens. In medicines they can arise from the synthesis of the active pharmaceutical ingredient, from recovered solvents and reagents, from nitrite impurities in excipients reacting with secondary or tertiary amines, and from contaminated starting materials. Why they matter: because the risk is cumulative over a lifetime of exposure, even very small amounts are controlled to strict limits expressed in nanograms per day.

Health Canada applies each AI limit to the maximum daily dose (MDD) of the drug product. Where a product can contain more than one nitrosamine, total exposure is held to the most conservative applicable limit, and any alternative calculation must keep the excess lifetime cancer risk at no more than 1 in 100,000. These principles did not change in November 2026, but the LTL update changes the number you compare against for short-course products.

The three-step program and why the elapsed timelines still matter

What it is: Health Canada's nitrosamine program has always run in three steps. Why it matters: all three deadlines have now passed, and Health Canada no longer considers requests for extensions, so a gap today is a live compliance exposure, not a planning item. What to do: confirm each of your products has a documented, current position at every step.

StepChemically synthesized and semi-synthetic APIsBiologics and radiopharmaceuticals
Step 1: Risk assessment31 March 202130 November 2021
Step 2: Confirmatory testing1 October 202230 November 2023
Step 3: Changes to the market authorization1 August 20251 August 2025

Because these dates have elapsed, a product that still lacks a risk assessment, or that has detections above an AI limit without a control strategy, is out of step with the guidance now. If your investigation and change-control records are not tight, read our guidance on deviation and out-of-specification investigations and on GMP change control, because both feed directly into how you document a nitrosamine finding and the market authorization change that follows.

The less-than-lifetime (LTL) framework and its limits

What it is: a scientifically justified way to consider the AI limit for a product that is not taken for a lifetime, because the cancer risk model is based on lifetime daily exposure. Why it matters: it informs how a short-course product is assessed, but the guidance states that LTL-based AI limits are not to be applied during or after the CAPA implementation timeline, so it is not a route to avoid reformulation or withdrawal. What to do: establish the realistic treatment duration, apply the correct factor to the established AI, and keep the justification in the risk assessment.

Health Canada aligns the adjustment with the ICH M7 approach. The established AI limit is treated as the lifetime value, and it is scaled by a factor that depends on how long a patient is actually exposed:

Duration of treatmentAdjustment to the established AI limit
Up to 1 month80 times the AI
More than 1 month up to 12 months13.3 times the AI
More than 1 year up to 10 years6.7 times the AI
More than 10 years up to lifetimeNo adjustment (use the AI as published)

A worked illustration makes the point. Suppose a nitrosamine has an established AI of 100 ng/day and your product is a 10-day antibiotic course. The lifetime limit of 100 ng/day could be adjusted up to 80 times, giving a short-course limit of 8,000 ng/day. A detection that looked like a failure against 100 ng/day may be well controlled against the adjusted value. The responsibility is on the MAH to justify the treatment duration honestly, to use the maximum realistic duration where a product is used repeatedly or chronically, and to document the calculation so an inspector can follow it.

Acceptable Intake limits: where they live now and how categories work

What changed: the established AI table, long known as Appendix 1, is no longer inside the guidance PDF. It is published on a separate, versioned Acceptable Intake limits page with an Excel download and a date-published column for each substance. Practically, you should link procedures and risk assessment templates to that page and check the version before you rely on a number.

Where a nitrosamine has no established AI, Health Canada uses the Carcinogenic Potency Categorization Approach (CPCA) to assign a category and a default limit. The categories are:

CPCA categoryDefault AI limit (ng/day)
Category 118
Category 2100
Category 3400
Category 41500
Category 51500

The CPCA excludes certain structures, including N-nitrosamides, N-nitrosoureas, N-nitrosoguanidines and nitroso groups within an aromatic ring, which are handled differently. A compound-specific limit derived from robust data, such as a TD50 from a carcinogenicity study, an enhanced Ames result or negative in vivo data, takes precedence over a CPCA default. For context, familiar established limits include 96 ng/day for NDMA and 26.5 ng/day for NDEA. When the March 2026 revision tightened several values, N-nitroso-meglumine moved to 100 ng/day, which shows how a single table change can turn a compliant result into a finding overnight.

Notification and recall: what to report, and when

What it is: the rule that governs when an MAH must contact Health Canada about a nitrosamine result. Why it matters: over-reporting wastes effort, while under-reporting a recall-level issue is a serious compliance failure. What to do: make the decision point a recall decision, not every elevated detection, and attach your confirmatory data when you notify.

Under the current guidance, MAHs are expected to notify Health Canada when a decision to initiate a recall is made, rather than at every elevated detection. If confirmatory testing shows that market action is warranted, Health Canada must be informed, and MAHs are asked to engage Health Canada before initiating the recall. The confirmatory testing results should accompany that notification. Recalls themselves follow Health Canada's recall guidance. The MAH decides whether a result above the applicable limit, whether an Appendix 1 value or a CPCA-derived one, requires market action, and must keep the risk assessment, analytical results and method validation ready in case Health Canada asks for them.

This is where supplier control earns its place. Many nitrosamine findings trace back to an API source, a recovered solvent or an excipient nitrite level. A risk-tiered supplier qualification programme and strong cleaning validation and cross-contamination control reduce the chance that a detection becomes a recall in the first place.

The CAPA window and your Step 3 changes

What it is: the time Health Canada allows to implement corrective and preventive action once an AI limit applies to your product. Why it matters: it sets a hard internal deadline for reformulation, resourcing or supplier changes. What to do: map each affected product to its CAPA end date and resource the work backwards from there.

For AI limits published before 1 August 2025, the CAPA timeline is up to three years from 1 August 2025, meaning up to 1 August 2028. For AI limits published on or after 1 August 2025, it is up to three years from that limit's publication date. Health Canada considers the AI limits appropriate for lifetime administration during the CAPA period, but its clear expectation is that MAHs reduce nitrosamine levels below the AI limits as soon as possible, not at the last moment. Step 3 changes are submitted through the Common Electronic Submission Gateway, in eCTD or non-eCTD format, with a covering letter that identifies the change as nitrosamine risk mitigation and a quality summary that captures the root-cause conclusions.

A nitrosamine control strategy is only as strong as the quality system around it. If your annual product quality review does not trend nitrosamine results, or your drug establishment licence scope does not match the sites doing the testing, those gaps surface during an inspection. Paediatric and liquid products deserve particular attention, as our note on excipient risk in paediatric oral suspensions explains, because low body weight drives tighter per-kilogram exposure.

Nitrosamine compliance checklist for Canadian MAHs

Use this checklist to test whether your program reflects the November 2026 guidance:

  • Confirm every product has a current Step 1 risk assessment that reflects the latest API, excipient and process information.
  • Re-point all procedures and templates to the current established Acceptable Intake limits page and record the version used in each assessment.
  • For short-course products, calculate the LTL-adjusted limit using the correct duration band, and document the duration rationale.
  • Verify maximum daily dose and treatment duration against the product monograph and real-world use before applying any factor.
  • Check confirmatory testing methods are validated, with a limit of quantitation at or below the applicable limit.
  • Map each affected product to its CAPA end date, including the 1 August 2028 date for pre-August-2025 limits.
  • Set the notification trigger to a recall decision, and keep confirmatory data ready to accompany any notification.
  • Trend nitrosamine results in your annual product quality review and escalate adverse trends through change control.
  • Confirm the testing sites and the change being filed sit within your drug establishment licence scope.

Common mistakes Health Canada inspectors see

A recurring finding is a risk assessment that was written once, in 2021, and never revisited. The guidance has changed several times since, and the AI table changes on its own schedule, so a static assessment drifts out of compliance. A second mistake is applying an LTL factor without a defensible duration, which inflates the limit and invites a challenge. A third is quoting an AI limit from an old copy of Appendix 1 after a value has been tightened. A fourth is treating a single elevated detection as an automatic notification, which creates noise, or the opposite, sitting on a recall-level result without engaging Health Canada. Finally, inspectors frequently find that method validation does not support the limit of quantitation claimed, which undermines every result built on it. Many of these map directly to weak batch failure and investigation practices, so fixing the investigation procedure often fixes the nitrosamine documentation too.

Frequently asked questions

What actually changed in Health Canada's nitrosamine guidance in November 2026?

Health Canada already recognised the less-than-lifetime framework for nitrosamine impurities, with adjustment factors tied to treatment duration, and it limits that use: LTL-based AI limits are not to be applied during or after the three-year CAPA implementation timeline. The guidance also confirms that the Acceptable Intake table has moved to a separate web page and restates the CAPA implementation window. The underlying three-step program and the notification approach were already in place.

How do the less-than-lifetime adjustment factors work?

The established AI limit is treated as the lifetime value and multiplied by a factor based on how long a patient is treated: up to 80 times for courses of one month or less, 13.3 times for more than one month up to a year, 6.7 times for more than one year up to ten years, and no adjustment beyond ten years. The MAH must justify the duration used.

Where do I find the current Acceptable Intake limits?

On Health Canada's dedicated established Acceptable Intake limits page, which carries a version date and an Excel download. The table is no longer inside the guidance PDF, so link your procedures to that page and check the version before relying on a value.

When must an MAH notify Health Canada about a nitrosamine result?

When a decision to initiate a recall is made. MAHs are asked to engage Health Canada before initiating the recall, and to send the confirmatory testing results with the notification. The MAH keeps the full risk assessment and analytical records available on request.

What is the deadline to bring levels below the AI limit?

For AI limits published before 1 August 2025, MAHs have up to 1 August 2028. For limits published on or after 1 August 2025, up to three years from that limit's publication date. Health Canada still expects levels to be reduced as soon as possible within that window.

Does the CPCA still apply if there is no established limit?

Yes. Where no established AI exists, the Carcinogenic Potency Categorization Approach assigns a category and a default limit, from 18 ng/day for Category 1 up to 1500 ng/day for Categories 4 and 5. A robust compound-specific limit takes precedence over a CPCA default.

Do these rules apply to natural health products or only to drugs?

The nitrosamine guidance applies to medications, that is, products with a Drug Identification Number, including prescription and non-prescription drugs, biologics and radiopharmaceuticals. Natural health products sit under a separate framework, although the same scientific principles for impurity control are good practice.

How MFLRC can help

MFLRC helps Market Authorization Holders, importers and manufacturers turn the nitrosamine guidance into a defensible, current control strategy. Our regulatory and quality teams carry out gap assessments against the November 2026 guidance, rebuild or update risk assessments, and perform the less-than-lifetime calculations with documented duration rationales that stand up to inspection. We help design confirmatory testing programs and method validation expectations, write the standard operating procedures that connect detection, investigation and notification, and prepare the Step 3 changes to the market authorization. We also strengthen the supporting systems, from supplier qualification and quality agreements to CAPA and annual product quality review, so a single detection does not become a recall.

If you are not sure whether your risk assessments reflect the current guidance, or you want a second set of eyes on an LTL calculation before you rely on it, we can help quickly.

Conclusion

The November 2026 revision is a reminder that nitrosamine control is not a project that finished when the Step 3 deadline passed in 2025. It is a living program. The less-than-lifetime framework is part of the picture for short-course products, but it is not a substitute for reducing levels, because Health Canada states that LTL-based AI limits are not to be applied during or after the three-year CAPA implementation timeline. The move of the AI table to its own page means your references need checking, and the CAPA window gives you a hard date to plan against. The MAHs who stay ahead of this will treat their risk assessments as controlled documents that are reviewed when the guidance or the AI table changes, not as a one-time exercise. That discipline is what an inspector rewards, and what keeps patients safe.

Sources and references

Downloadable Resource

Nitrosamine Risk Assessment and AI-Limit Review Checklist

A step-by-step checklist to bring your nitrosamine risk assessments, less-than-lifetime calculations and notification procedures in line with Health Canada's November 2026 guidance.

File: MFLRC-Nitrosamine-Nov2026-Checklist.pdf

Share with others

Tags

Nitrosamine ImpuritiesPharmaceuticalsHealth CanadaComplianceQuality Management System
Book a consultation